{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T15:55:34Z","timestamp":1777564534103,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014487","name":"Clovis Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010544","name":"Exelixis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010544","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013767","name":"ACEA Biosciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013767","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.lungcan.2020.09.006","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T12:39:05Z","timestamp":1600346345000},"page":"97-102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Everolimus in the treatment of metastatic thymic epithelial tumors"],"prefix":"10.1016","volume":"149","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3366-6805","authenticated-orcid":false,"given":"Jessica A.","family":"Hellyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3422-1675","authenticated-orcid":false,"given":"Madhu M.","family":"Ouseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8691-7754","authenticated-orcid":false,"given":"Sukhmani K.","family":"Padda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1136-980X","authenticated-orcid":false,"given":"Heather A.","family":"Wakelee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"May (5)","key":"10.1016\/j.lungcan.2020.09.006_bib0005","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1586\/era.12.29","article-title":"Chemotherapy and targeted agents for thymic malignancies","volume":"12","author":"Girard","year":"2012","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"June (6)","key":"10.1016\/j.lungcan.2020.09.006_bib0010","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1200\/JCO.1994.12.6.1164","article-title":"Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern cooperative oncology group, Southwest oncology group, and southeastern cancer study group","volume":"12","author":"Loehrer","year":"1994","journal-title":"J. Clin. Oncol."},{"issue":"May (15)","key":"10.1016\/j.lungcan.2020.09.006_bib0015","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1200\/JCO.2010.32.9607","article-title":"Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma","volume":"29","author":"Lemma","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"December (36)","key":"10.1016\/j.lungcan.2020.09.006_bib0020","doi-asserted-by":"crossref","first-page":"4820","DOI":"10.1200\/JCO.2011.36.0487","article-title":"Thymic malignancies: from clinical management to targeted therapies","volume":"29","author":"Kelly","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2020.09.006_bib0025","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11864-017-0495-8","article-title":"Novel agents in the treatment of thymic malignancies","volume":"18","author":"Merveilleux du Vignaux","year":"2017","journal-title":"Curr. Treat. Options Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2020.09.006_bib0030","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol."},{"issue":"September (9 Suppl 2)","key":"10.1016\/j.lungcan.2020.09.006_bib0035","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1097\/JTO.0000000000000298","article-title":"State of the art of genetic alterations in thymic epithelial tumors","volume":"9","author":"Rajan","year":"2014","journal-title":"J. Thorac. Oncol."},{"issue":"February (2)","key":"10.1016\/j.lungcan.2020.09.006_bib0040","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The integrated genomic landscape of thymic epithelial tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"issue":"February (2)","key":"10.1016\/j.lungcan.2020.09.006_bib0045","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1470-2045(14)71181-7","article-title":"Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial","volume":"16","author":"Thomas","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.lungcan.2020.09.006_bib0050","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.lungcan.2016.04.024","article-title":"Sunitinib in patients with advanced thymic malignancies: cohort from the French RYTHMIC network","volume":"97","author":"Remon","year":"2016","journal-title":"Lung Cancer"},{"issue":"February (4)","key":"10.1016\/j.lungcan.2020.09.006_bib0055","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1200\/JCO.2017.74.4078","article-title":"Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy","volume":"36","author":"Zucali","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"May (5)","key":"10.1016\/j.lungcan.2020.09.006_bib0060","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat. Med."},{"issue":"January (1)","key":"10.1016\/j.lungcan.2020.09.006_bib0065","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/CJI.0000000000000006","article-title":"Immunomodulatory effects of everolimus in a long responsive patient with metastatic renal cell carcinoma","volume":"37","author":"Thiery-Vuillemin","year":"2014","journal-title":"J Immunother"},{"key":"10.1016\/j.lungcan.2020.09.006_bib0070","doi-asserted-by":"crossref","first-page":"7336","DOI":"10.1038\/srep07336","article-title":"Mutations of epigenetic regulatory genes are common in thymic carcinomas","volume":"4","author":"Wang","year":"2014","journal-title":"Sci. Rep."},{"issue":"July (3)","key":"10.1016\/j.lungcan.2020.09.006_bib0075","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s12253-016-0144-8","article-title":"Molecular profiling of thymoma and thymic carcinoma: genetic differences and potential novel therapeutic targets","volume":"23","author":"Enkner","year":"2017","journal-title":"Pathol. Oncol. Res."},{"issue":"July (7511)","key":"10.1016\/j.lungcan.2020.09.006_bib0080","first-page":"543","article-title":"Comprehensive molecular profiling of lung adenocarcinoma","volume":"511","author":"Network CGAR","year":"2014","journal-title":"Nature"},{"issue":"September (7417)","key":"10.1016\/j.lungcan.2020.09.006_bib0085","first-page":"519","article-title":"Comprehensive genomic characterization of squamous cell lung cancers","volume":"489","author":"Network CGAR","year":"2012","journal-title":"Nature"},{"issue":"January (1)","key":"10.1016\/j.lungcan.2020.09.006_bib0090","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1158\/1078-0432.CCR-19-1237","article-title":"Role of KEAP1\/NFE2L2 mutations in the chemotherapeutic response of patients with non-small cell lung Cancer","volume":"26","author":"Jeong","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"December (6)","key":"10.1016\/j.lungcan.2020.09.006_bib0095","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.ccell.2017.11.006","article-title":"Genomic aberrations that activate D-type cyclins are associated with enhanced sensitivity to the CDK4 and CDK6 inhibitor abemaciclib","volume":"32","author":"Gong","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.lungcan.2020.09.006_bib0100","first-page":"9085","volume":"37","author":"Paik","year":"2019"},{"issue":"November (11)","key":"10.1016\/j.lungcan.2020.09.006_bib0105","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/nm.4407","article-title":"Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis","volume":"23","author":"Romero","year":"2017","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2020.09.006_bib0110","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13045-019-0754-1","article-title":"Targeting mTOR for cancer therapy","volume":"12","author":"Hua","year":"2019","journal-title":"J. Hematol. Oncol."},{"issue":"9","key":"10.1016\/j.lungcan.2020.09.006_bib0115","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1002\/1878-0261.12078","article-title":"K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines","volume":"11","author":"Yeung","year":"2017","journal-title":"Mol. Oncol."},{"issue":"July (7)","key":"10.1016\/j.lungcan.2020.09.006_bib0120","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/annonc\/mdv166","article-title":"Clinical usefulness of PI3K\/Akt\/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines","volume":"26","author":"Bodnar","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2020.09.006_bib0125","doi-asserted-by":"crossref","DOI":"10.14694\/EdBook_AM.2013.33.e395","article-title":"Targeting the PI3K\/AKT\/mTOR pathway: biomarkers of success and tribulation","author":"Owonikoko","year":"2013","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"issue":"December(25)","key":"10.1016\/j.lungcan.2020.09.006_bib0130","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1093\/hmg\/10.25.2899","article-title":"Pathological mutations in TSC1 and TSC2 disrupt the interaction between hamartin and tuberin","volume":"10","author":"Hodges","year":"2001","journal-title":"Hum. Mol. Genet."},{"issue":"August (8)","key":"10.1016\/j.lungcan.2020.09.006_bib0135","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.1172\/JCI37539","article-title":"Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus","volume":"120","author":"Di Nicolantonio","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.lungcan.2020.09.006_bib0140","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s12967-015-0399-y","article-title":"Personalization of cancer treatment using predictive simulation","volume":"13","author":"Doudican","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.lungcan.2020.09.006_bib0145","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.leukres.2018.11.010","article-title":"Predicting response to BET inhibitors using computational modeling: a BEAT AML project study","volume":"77","author":"Drusbosky","year":"2019","journal-title":"Leuk. Res."},{"key":"10.1016\/j.lungcan.2020.09.006_bib0150","first-page":"382","article-title":"Identification of molecular subtypes of thymic epithelial tumors and novel treatments using a computational biological model","author":"Gokmen-Polar","year":"2018","journal-title":"IASLC 19th World Conference on Lung Cancer."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220306048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500220306048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:46:24Z","timestamp":1759236384000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500220306048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":30,"alternative-id":["S0169500220306048"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.09.006","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Everolimus in the treatment of metastatic thymic epithelial tumors","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2020.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}